Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D Replacement in Patients With Urolithiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 25-OHD deficiency or insufficiency (defined as serum level \<75 nmol/L).~* History of urolithiasis (Calcareous stones).~* 24-hour urinary calcium excretion \<7.5 mmol/day (normocalciuric).~* Low fracture risk (estimated by FRAX®, which was developed by WHO).~Exclusion Criteria:~* Age \< 18 years~* Renal dysfunction (Serum creatinine concentrations of \> 150 μmol/L).~* History of non-calcareous stones e.g. uric acid, cystine, or struvite stones.~* Hypercalcemia (serum ionized normalized calcium \> 1.32 mmol/L)~* Patients with secondary hypercalciuria e.g. primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or active malignancy.~* Evidence of osteoporosis or intermediate/high fracture risk (estimated by FRAX).~* Patients taking drugs that could potentially affect urinary calcium excretion (vitamin D, calcium supplement, loop diuretics, steroids, or lithium).~* Evidence of liver dysfunction or other disorders that may cause non-nutritional vitamin D deficiency or abnormal bone development.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No vitamin D replacement (Type: None): The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (\>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
- Vitamin D3 tabs (Type: None): The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).